Fluidigm Announces Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
06 juil. 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Present at Upcoming Health Care Investor Conferences
13 mai 2020 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results
20 avr. 2020 16h06 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Completes Acquisition of InstruNor AS
26 févr. 2020 08h30 HE
|
Fluidigm Corporation
Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep SOUTH SAN FRANCISCO, Calif., Feb. ...
Fluidigm to Participate in Upcoming Investor Conferences
12 févr. 2020 16h05 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h05 HE
|
Fluidigm Corporation
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates...
Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services
10 févr. 2020 08h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life...
Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
14 janv. 2020 08h30 HE
|
Fluidigm Corporation
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year ...
Fluidigm Receives Life Science Industry Award for the Maxpar Direct Immune Profiling System
09 déc. 2019 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioInformatics Inc., the leading research and advisory firm serving the life science tools market, recognized Fluidigm...